Tsunenori Kondo

50PUBLICATIONS
31CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsChemotherapyPredictive and prognostic markersRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|May 07, 2026
Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.

|Mar 02, 2026
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.

Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto

|Feb 16, 2026
Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors.

Yuki Nemoto, Hiroki Ishihara, Hironori Fukuda

|Jan 27, 2026
Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.

Hiroki Ishihara, Yu-Yu Liu, Riu Yamashita

|Dec 18, 2025
Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations.

Nanaka Katsurayama, Hiroki Ishihara, Toshihito Hirai

|Sep 30, 2025
Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma.

Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto

Pageof 9

Frequent Collaborators

22 joint publications

Toshio Takagi

13 joint publications

Kazuhiko Yoshida

7 joint publications

Tsunenori Kondo

2 joint publications

Toshikazu Ushijima